Just hours after the WHO declared the end of Ebola virus transmission in the outbreak region, the agency confirms a new, fatal case.
The WHO also warned of the risk of flare-ups due to ligering virus in some survivors, a threat it says will decline with time.
Experts called together in the wake of the Ebola crisis laid out ways to better prepare for the next threat.
Johnson & Johnson's prime-boost Ebola vaccine regimen is entering phase 2 clinical trials in both healthy and HIV-infected people, the Walter Reed Army Institute of Research (WRAIR) announced yesterday in a press release.
Also, a short report notes gender differences during the outbreak, such as higher survival in females.
Social networks, though, were strong in poorer areas, which helped with disease control.
Forty-two days (two incubation periods) after its last Ebola patient tested negative for the virus, Guinea has been declared Ebola-free by the World Health Organization (WHO), leaving only Liberia to achieve that status in the outbreak region of West Africa, the WHO said in a news release.
After going 9 days without reporting a MERS-CoV infection, Saudi Arabia's Ministry of Health (MOH) confirmed a case yesterday.
Researchers used detailed exams in survivors to document eye problems, a common finding.
The World Health Organization (WHO) said that Ebola virus infection in West Africa continues to constitute a Public Health Emergency of International Concern (PHEIC), largely due to the potential for transmission of the virus from survivors and convalescent populations, according to a Dec 18 statement.
